This Article Full Text Full Text (PDF) CME: Take the course for this article: Monoclonal Antibody Therapy in Lymphoid Malignancies eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hainsworth, J. D. Search for Related Content PubMed PubMed Citation Articles by Hainsworth, J. D.

Monoclonal Antibody Therapy in Lymphoid Malignancies

The Sarah Cannon Cancer Center, Centennial Medical Center, Nashville, Tennessee, USA

Correspondence: John D. Hainsworth, M.D., The Sarah Cannon Cancer Center, 250 25th Avenue North, Suite 412, Nashville, Tennessee 37203, USA. Telephone: 615-342-1725; Fax: 615-342-1745; e-mail: jhainsworth{at}tnonc.com

ABSTRACT

The concept of targeted therapy for patients with advanced cancer has intrigued researchers for many years. The lymphoid malignancies are particularly good candidates for this therapeutic approach, due to the identification of multiple lymphocyte-specific antigens. The recent introduction of rituximab marks the beginning of a new era in the treatment of lymphoid malignancies. Rituximab is one of the most active single agents for patients with refractory indolent lymphoma, producing response rates of approximately 50%, with low toxicity and a brief duration of treatment. Additional uses of rituximab are being evaluated in ongoing clinical trials, and are briefly reviewed. As a first-line agent, responses of approximately 70% are produced in patients with indolent lymphoma, with minimal toxicity. A substantial percentage of patients can be successfully retreated with rituximab, with second remission durations longer than the first remission (14-16 months versus 12 months). Multiple combination regimens using rituximab plus chemotherapy are also being evaluated. Although the role of these combined approaches is incompletely defined, high complete response rates can be obtained, with a higher rate of molecular complete remission (i.e., eradication of detectable bcl-2 rearrangements) than has been observed in patients receiving chemotherapy alone. Rituximab is also being evaluated in other CD20⁺ lymphoid malignancies including large-cell lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. Within the next 12 months, several additional monoclonal antibodies will be available for the treatment of lymphoid malignancies. These include the radioimmunoconjugates tositumomab (Bexxar) and ibritumomab (Zevalin), as well as Campath-1H (anti-CD52) monoclonal antibody. Early clinical data with each of these agents are also briefly reviewed.

Key Words. Indolent lymphoma • Large-cell lymphoma • Monoclonal antibodies • Rituximab • Radioimmunoconjugates